From the Division of Cardiovascular Medicine, University of Wisconsin-Madison, Wisconsin.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
ASAIO J. 2021 Apr 1;67(4):430-435. doi: 10.1097/MAT.0000000000001249.
Patients are admitted to the hospital for hemodynamic optimization before left ventricular assist device (LVAD) implantation. The aim of this study was to evaluate the clinical outcomes of hemodynamic optimization using an intra-aortic balloon pump (IABP) in ambulatory heart failure patients before LVAD placement. This retrospective single-center study included 199 noninotrope-dependent patients who underwent durable LVAD implantation between January 1, 2007 and April 10, 2017. Invasive hemodynamic as well as the primary composite end-point of stage 2 or 3 acute kidney injury, right ventricular failure, and 30-day mortality were compared between patients with and without an IABP. Median age was 64 (interquartile range [IQR], 57-71) years and 165 (82.9%) were male; 72 (36.2%) received an IABP. Patients treated with an IABP had worse baseline exercise capacity and hemodynamic parameters. Patients with an IABP had greater relative reduction in pulmonary artery mean pressure (-16% vs. -2%; p ≤ 0.001). The primary composite end-point was not different between patients who had an IABP and those who did not (20.8% vs. 20.5%; p = 0.952), as were each of the individual end-points. Despite worse baseline hemodynamic parameters and exercise capacity, ambulatory heart failure patients who received an IABP before LVAD implantation had more favorable reductions in pulmonary artery pressures without an increase in the composite end-point. These results suggest that IABP use before LVAD implantation may mitigate the risk of postoperative complications in ambulatory patients.
患者在植入左心室辅助装置 (LVAD) 前被收入医院进行血液动力学优化。本研究旨在评估在 LVAD 放置前使用主动脉内球囊泵 (IABP) 对门诊心力衰竭患者进行血液动力学优化的临床结果。这项回顾性单中心研究纳入了 199 例 2007 年 1 月 1 日至 2017 年 4 月 10 日期间接受永久性 LVAD 植入的非正性肌力依赖患者。比较了有和没有 IABP 的患者之间的有创血液动力学以及 2 级或 3 级急性肾损伤、右心衰竭和 30 天死亡率的主要复合终点。中位年龄为 64(四分位距 [IQR],57-71)岁,165 例(82.9%)为男性;72 例(36.2%)接受了 IABP。接受 IABP 治疗的患者基线运动能力和血液动力学参数较差。接受 IABP 治疗的患者肺动脉平均压降低的相对幅度更大(-16%对-2%;p ≤ 0.001)。有 IABP 的患者与无 IABP 的患者的主要复合终点没有差异(20.8%对 20.5%;p = 0.952),每个单独的终点也没有差异。尽管基线血液动力学参数和运动能力较差,但在 LVAD 植入前接受 IABP 的门诊心力衰竭患者在肺动脉压力降低方面获益更多,而复合终点没有增加。这些结果表明,在 LVAD 植入前使用 IABP 可能会降低门诊患者术后并发症的风险。